Factors associated with the clinical outcome of patients with relapsed/refractory CD19+ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy

J Immunother Cancer. 2021 Dec;9(12):e003644. doi: 10.1136/jitc-2021-003644.
No abstract available

Keywords: adoptive; cell engineering; chimeric antigen; immunotherapy; receptors.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antigens, CD19 / immunology*
  • Cell- and Tissue-Based Therapy / methods*
  • Child
  • Child, Preschool
  • Drug Resistance, Neoplasm*
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / immunology
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Recurrence, Local / therapy*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
  • Prognosis
  • Receptors, Antigen, T-Cell / immunology*
  • Salvage Therapy*
  • Survival Rate
  • Young Adult

Substances

  • Antigens, CD19
  • CTL019 chimeric antigen receptor
  • Receptors, Antigen, T-Cell